Syros Pharmaceuticals Inc
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute mye… Read more
Syros Pharmaceuticals Inc - Asset Resilience Ratio
Syros Pharmaceuticals Inc (SYRS) has an Asset Resilience Ratio of 18.39% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2023)
This chart shows how Syros Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Syros Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $24.78 Million | 18.39% |
| Total Liquid Assets | $24.78 Million | 18.39% |
Asset Resilience Insights
- Good Liquidity Position: Syros Pharmaceuticals Inc maintains a healthy 18.39% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Syros Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Syros Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Syros Pharmaceuticals Inc (2014–2023)
The table below shows the annual Asset Resilience Ratio data for Syros Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | $0.00 | $168.17 Million | -- |
| 2022-12-31 | 14.25% | $34.84 Million | $244.49 Million | -6.56pp |
| 2021-12-31 | 20.81% | $38.07 Million | $182.94 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $213.25 Million | -- |
| 2019-12-31 | 33.32% | $49.98 Million | $149.98 Million | -13.32pp |
| 2018-12-31 | 46.64% | $49.79 Million | $106.77 Million | -4.13pp |
| 2017-12-31 | 50.76% | $39.84 Million | $78.49 Million | +23.38pp |
| 2016-12-31 | 27.38% | $25.00 Million | $91.32 Million | -29.93pp |
| 2015-12-31 | 57.31% | $25.00 Million | $43.63 Million | +16.65pp |
| 2014-12-31 | 40.66% | $25.00 Million | $61.49 Million | -- |